Oragenics INC

Oragenics, Inc. announced the appointment of John Spencer as Chief Financial Officer and shareholder approval for a reverse stock split, alongside director re-elections and auditor ratification.

Oragenics provides an update on its Phase IIa ONP-002 trial in Australia, patient enrollment progress, and a Letter of Intent for a complementary CNS medical device.

Oragenics, Inc. has signed a Letter of Intent to license Sigyn Therapeutics' CardioDialysis technology, aiming to target Traumatic Brain Injury (TBI) induced systemic inflammation.

Oragenics has dosed the first patient in its Phase IIa clinical trial for ONP-002, a potential treatment for concussion and mild traumatic brain injury, in Australia.

Oragenics, Inc. announced a change in the date for its 2025 Annual Meeting of Shareholders to June 29, 2026, setting a new deadline for shareholder proposals.

Oragenics, Inc. amended its At-the-Market Sales Agreement with Dawson James Securities Inc. to extend the term for future common stock sales.

Oragenics reports significant capital raise and progress on its lead neurological drug candidate ONP-002, while addressing ongoing financial challenges and regaining NYSE compliance.

Oragenics, Inc. reported reduced Q2 losses and secured $15.2 million in post-quarter financing, extending its cash runway through the first half of 2026, while advancing its lead drug candidate ONP-002 for concussion.

Oragenics, a development-stage company, announced its financial results for the first quarter of 2025, highlighting its focus on developing ONP-002 for mild traumatic brain injury.

Oragenics Inc. reported its third quarter 2024 results, highlighting a strategic shift towards the development of its ONP-002 drug for mild traumatic brain injury while managing financial constraints.

Oragenics, Inc. reported its financial results for the second quarter of 2024, highlighting a strategic shift towards developing its brain injury treatment, ONP-002, while managing financial constraints.

Oragenics, Inc. reported a net loss of $2.45 million for the first quarter of 2024, while shifting its focus to the development of ONP-002 for mild traumatic brain injury.

Oragenics, Inc. reports continued operating losses and a going concern doubt, while advancing its lead mild traumatic brain injury drug candidate, ONP-002, into Phase 2a clinical trials in Q1 2026.

Oragenics reports a net loss for 2024 and focuses on developing its brain injury drug, ONP-002, while navigating financial uncertainties and litigation.

Oragenics, Inc.'s annual 10-K filing provides a comprehensive overview of its capital structure, including common and preferred stock details, and outlines the regulatory environment impacting its pharmaceutical development.

Oragenics Inc. reports that Chief Financial Officer John Spencer was granted employee stock options.

ORAGENICS Director Fred Telling filed an amended Form 4, disclosing a sale of 210 common shares and the grant of 125,000 stock options, while correcting previous beneficial ownership due to a reverse stock split.

ORAGENICS Inc.'s CEO and CFO, Janet Huffman, was granted 250,000 employee stock options with an exercise price of $0.93, vesting over three years.

Natasha Giordano, a Director at ORAGENICS INC, was granted 163,320 stock options as part of her non-employee director compensation program.

ORAGENICS Director Fred Telling reported the sale of 210 common shares and the grant of 125,000 stock options under the company's incentive plan.

Oragenics Director John P. Gandolfo received an immediate grant of 125,000 stock options with an exercise price of $0.93, vesting immediately under the company's equity incentive plan.

Oragenics issues a supplement to its proxy statement clarifying the classification of proposals as routine or non-routine for broker voting purposes at the upcoming 2024 Annual Meeting of Stockholders.

Oragenics, Inc. is asking shareholders to vote on proposals including a reverse stock split, an increase in authorized shares, and an amendment to the company's equity incentive plan at its upcoming annual meeting.

Oragenics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Oragenics, Inc. is holding its 2023 Annual Meeting of Shareholders on December 11, 2024, to vote on key proposals including the election of directors, executive compensation, and an amendment to the company's equity incentive plan.

Oragenics, Inc. has filed an amendment to its registration statement to facilitate a new securities offering, aiming to raise at least $15 million in gross proceeds to address its immediate liquidity needs and mitigate substantial doubt about its ability to continue as a going concern beyond Q3 2025.

Oragenics, Inc. is seeking to raise up to $20 million through an offering of Series H Preferred Stock and Warrants to fund its ONP-002 concussion clinical trials and address significant financial challenges, including an auditor's going concern doubt and NYSE American listing non-compliance.

Oragenics is launching a public offering of up to 15,151,515 units to fund the development of its ONP-002 drug for mild traumatic brain injury.

Oragenics, Inc. is conducting a public offering of up to 15,151,515 units to fund the development of its ONP-002 concussion treatment and for general corporate purposes.

Oragenics, Inc. is launching a public offering of up to 15,151,515 units to raise capital for its ONP-002 concussion treatment and other corporate purposes.

Oragenics, Inc. announces a public offering of common stock and pre-funded warrants to raise up to $5 million for its ONP-002 concussion treatment and general corporate purposes.

Sabby Management, Hal Mintz, and Sabby Volatility Warrant Master Fund, Ltd. have disclosed a combined 9.9% beneficial ownership in Oragenics Inc. common stock.

Five Narrow Lane LP has filed a Schedule 13G, reporting a 9.99% beneficial ownership stake in Oragenics, Inc., representing 82,210 shares.